GLPwatch
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
Diabetes Obes Metab · 2025
Last updated 2026-05-28| Journal | Diabetes Obes Metab, 2025 |
|---|---|
| Citations | 4 |
| Molecules | survodutide |
| Conditions studied | Obesity, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 39582349 ↗
Related research
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
- Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
- Perspectives in weight control in diabetes - Survodutide.
- The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
- Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
- Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.